Furthermore, increased serum levels of alanine aminotransferase (ALT) and cytokeratin-18 (CK18) fragments, two markers associated with liver damage as well as NAFLD/NASH, are applicable to predict NASH progression in morbidly obese patients [71–75]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.